45 results about "Helminths" patented technology

The invention discloses a tissue adhesive based on mussel mucin as well as a preparation method and application thereof. The tissue adhesive is prepared from mussel mucin and an anionic compound containing a hydrophobic group, the mussel worm electrostatic self-assembly bionic composite material is developed on the basis of triple bionic principles of dopa adhesion of mussel byssus, electrostatic self-assembly polymerization of sandburg worms and hydrophobic acting force of barnacles. The preparation method of the tissue adhesive is simple, the tissue adhesive can be obtained only by mixing and oscillating the two stock solutions, the gel forming condition is simple and easy to implement, the pH range and the stock solution concentration range required by gel forming are large, the gel forming range is wide, the raw materials required in the preparation process are few, and the cost is low. Only two key raw materials including the mussel mucin and the anionic compound containing the hydrophobic group are needed, and the prepared tissue adhesive is high in adhesion speed and high in adhesion strength, has good cell compatibility and biological safety and can promote wound healing.

Fishing jigs designed and configured to firmly hold natural worms during use. In some embodiments, a fishing jig includes a head, a shaft that tapers away from the head, and an impaler that pierces the entire thickness of the body wall of a worm. The cross-sectional size of the shaft proximate to the impaler is selected so that the body wall of the worm is taut when the worm is fully engaged with the fishing jig. In some embodiments, the impaler is angled toward the head of the fishing jig at an angle of 45° or less. In some embodiments, the fishing jig further includes a bumper on its bottom to assist with inhibiting a worm engaged with the fishing jig from catching on underwater objects.

The present invention relates to novel enzymatically inactive structural polypeptides derived from the N-terminal part of heGDH (helminthic glutamate dehydrogenase), therapeutical methods based thereon and uses thereof.

A cold rotting device (10) in the manner of a worm composter, particularly for kitchen waste, particularly suitable for indoor spaces and private households, configured to provide a habitat for worms decomposing kitchen waste, comprising a cavity (11) receiving the kitchen waste and providing the habitat, and at least one partition (12, 12a) segmenting or sealing off the cavity, which partition can be positioned at a plurality of, in particular, form-fitting, predefined spatial separation positions or separation lines (13) on / in the cavity (11); characterized in that the plurality of predefined spatial separation positions or separation lines (13) segment the cavity (11) in at least one horizontal spatial direction (u) and, when the partition (12, 12a) is positioned there, each seals off the worms against horizontal migration.

This item is a lure (worm) used for octopus fishing. It is made of a flexible material and shaped to resemble a crustacean such as a crayfish. It is used attached to a hook rig, for example, as shown in the "Reference Diagram Showing the Names of Each Part." In this example, the hook rig consists of a core rod with a fishing hook, a ball, and a worm attachment rod. This item has a hook rig attachment hole, as shown in the "AA Cross-Sectional View." Therefore, as shown in the "Reference Perspective View from the Rear Side Showing the Usage State," the worm attachment rod is passed through the hook rig attachment hole, and the hook at the tip of the worm attachment rod is hooked onto the core rod, thereby attaching the item to the hook rig. As shown in red in the "Reference Diagram Showing Air Pockets," air is trapped inside the areas corresponding to the claws and tail. Therefore, during use, buoyancy in the sea tends to cause the air pockets to face upwards. Therefore, when it lies on the seabed (with the longitudinal direction of the needle arrangement aligned with the seabed), the surface shown in the front view tends to face upwards, and the surface shown in the rear view tends to face downwards (towards the seabed). In other words, when viewed from above, the item is likely to land in the state shown in the front view. Moreover, the claws are raised, mimicking the intimidation behavior of crustaceans.

The present invention discloses a sludge reduction device with a special structure to strengthen the stable attachment of worms. The device comprises a housing, a worm packing box, a porous conveyor belt, a mud inlet assembly, a water inlet assembly, an aeration assembly, and a drainage assembly. The worm packing box is connected to a fixed plate by a connecting rod. The fixed plate is provided with a mounting rod, which is connected to the housing. Rollers are provided on all four sides of the fixed plate. Rollers are fixedly sleeved on the four rollers. The four rollers are connected by a linkage belt transmission. The porous conveyor belt is provided with a plurality of slots, and a plurality of holes are evenly provided in the slots. The porous conveyor belt is tensioned and mounted on the rollers. A drive assembly is connected to the rollers. The mud inlet assembly and the water inlet assembly are both arranged above the porous conveyor belt. The aeration assembly and the drainage assembly are both installed in the housing. The present invention realizes efficient utilization and long-term stable operation of the worms, improves the dispersibility and attachment density of the worms, and realizes efficient and stable treatment of sewage sludge.

Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli, the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium bovis, or Enterobacter cloacae. The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. Further embodiments provide compositions comprising arsinothricin or a salt thereof and an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.

Praziquantel may be formulated to enhance its pharmacokinetic, toxicity, and palatability properties. It can be stored and / or dispensed as a liquid, powder, or tablet. Reduction in the most common side effects improves patient compliance and satisfaction. Altered taste profile improves patient compliance and satisfaction. Once formulated it can be used to treat a variety of blood flukes and worms in human and veterinary subjects.

A method of mitigating and rehabilitating soil and land areas contaminated with forever chemicals such as PFAS (perfluoroalkyl and polyfluoroalkyl) based toxins involves manipulating genetic nucleotides of carrier organisms for expressing an enzyme reactive with the forever chemicals for rendering them benign. The carrier organisms pass the modified DNA that enables the enzyme to subsequent generations for maintaining an active population of enzyme-expressing organisms, typically worms, once introduced.

This invention provides for compounds of the formula:wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and methods for the treatment, control and / or prevention of a parasitic infestation and / or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.

The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in Pichia pastoris. More specifically, the invention describes the production of Sm14 Schistosoma mansoni recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of Pichia pastoris promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, Pichia pastoris strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from P. pastoris cells, which can be escalated for their industrial production, were also improved.

Systems, devices, and methods for managing air gaps in a semiconductor device are provided. In one aspect, a method includes removing coelomic fluid from an exterior surface of the worms using a drying agent; removing blood from the worms; performing centrifugation on the blood to generate a blood supernatant; concentrating, by a tangential flow filtration system with a single membrane, the blood supernatant to form a concentrated blood product; and performing, by the tangential flow filtration system, tangential flow filtration of a diafiltration mixture comprising the concentrated blood product.

The present invention relates to the use of N-methoxy(phenylethyl)-pyrazole carboxamides for the control of nematodes in agriculture and as antihelminthic agents against endoparasites in animals and humans, as well as compositions comprising such compounds. The present invention 5 further relates to the use of these compounds or compositions for controlling nematodes and / or helminths, in particular for controlling plant parasitic nematodes, and to the use of these compounds in preparing nematicidal and / or antihelminthic compositions.

A fixative contains carboxylic acid, preferably acetic acid, for parasitological samples. An exemplary aqueous fixative solution for parasitological samples comprises: a) a C2 to C6 carboxylic acid (preferably acetic acid) at a concentration of 0.5M or greater; and b) a C2 to C6 carboxylate salt or halide salt at a concentration of 0.02M or greater, preferably 0.04M or greater. An optional composition comprises 1.3M acetic acid, 12 mM sodium benzoate, 0.9% calcium chloride, 0.9% calcium bromide, 100 μg / ml menthol and 350 μg / ml thymol. The fixative is free of formaldehyde or other hazardous compounds, and exhibits good killing and staining properties when used with parasitological samples such as ova and helminths.

The present invention relates to a veterinary vaccine composition based on fatty-acid-binding proteins (FABP) from parasites. Specifically, the invention discloses a veterinary vaccine composition based on the Schistosoma mansoni protein (rSm14) or homologous proteins of Fasciola hepatica (FhFABPs) that provide a homogeneous, long-term immune response against parasitic worms. The invention is also intended to provide a method for treating and preventing infection caused by parasitic worms, in particular Fasciola hepatica, and also the use of these proteins in a vaccine composition against parasitic worms.

This invention provides the application of Usnea powder, Usnea acid, or sodium usneate (or Usnea powder, Usnea acid, or sodium usneate as the sole active ingredient) in the preparation of broad-spectrum antiparasitic drugs for aquatic animals, drugs for treating complications caused by parasitic infections, feed additives, or functional feeds. By utilizing Usnea, Usnea extract, Usnea acid, and Usnea salts, various parasites, including ciliates, worms, and protozoa, that infest the surface and interior of aquatic animals during aquaculture can be eliminated or killed, thus maintaining the health of farmed animals, improving the success rate of aquaculture, achieving broad-spectrum and highly effective prevention and control of aquatic animal parasitic diseases, reducing the use of chemical drugs, and providing good aquaculture, ecological, and social benefits. It is safe, broad-spectrum, and highly effective, facilitating large-scale promotion.

The present disclosure provides compounds, pharmaceutical compositions, and methods useful for treating parasitic worms. The compound is a benzodiazepine type structure substituted at C3 according to Formula I, Formula II, Formula III, Formula IV, or Formula V. In various aspects, the presently described treatment can advantageously provide anthelmintic effects with reduced sedative qualities.

The present invention relates to microparticles containing moxidectin and a method for producing the same, which, unlike conventional heartworm preventive drugs that have a short half-life and must be administered daily or monthly, when microparticles containing moxidectin are administered, moxidectin is continuously released for more than three months, thereby maintaining the preventive effect against heartworms. In addition, by producing microparticles with a constant average particle diameter and a narrow diameter distribution, it is possible to prevent initial excessive release of moxidectin even when the microparticles are administered, and to control the release of the drug to maintain a constant concentration of effective moxidectin for more than three months, thereby reducing foreign body sensation and pain when the injection is administered.

A method of mitigating and rehabilitating soil and land areas contaminated with forever chemicals such as PFAS (perfluoroalkyl and polyfluoroalkyl) based toxins involves manipulating genetic nucleotides of carrier organisms for expressing an enzyme reactive with the forever chemicals for rendering them benign. The carrier organisms pass the modified DNA that enables the enzyme to subsequent generations for maintaining an active population of enzyme-expressing organisms, typically worms, once introduced.

The invention belongs to the technical field of application of surfactants, and particularly relates to a pH response type wormlike micelle and a preparation method thereof. According to the wormlike micelle provided by the invention, a multifunctional reactive surfactant and oxalic acid are utilized to form a quasi-gemini surfactant, and the quasi-gemini surfactant is self-assembled at room temperature to form the wormlike micelle with viscoelasticity. The obtained wormlike micelle has pH stimulation responsiveness, and the viscoelasticity of the system is obviously changed along with the change of pH. Firstly, a certain mass of oxalic acid is dissolved in deionized water, and after the oxalic acid is fully dissolved, the multifunctional reaction type surfactant with the corresponding proportion is added. The preparation method comprises the following steps: completely dissolving at room temperature by utilizing a stirring method, and standing for one night to fully balance, so as to obtain stable wormlike micelles. The wormlike micelle obtained by the invention is simple in preparation method, easy to regulate and control, sensitive to pH change and quick in response.

To provide new anthelmintic compounds that can, for example, be used in the treatment of the kind of worm disease caused by helminths such as Dirofilaria, in particular Dirofilaria immitis.SOLUTION: There is provided a compound of Formula (I) or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug and mixtures thereof.SELECTED DRAWING: None

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The present invention relates to microparticles containing moxidectin and a method for producing the same, which, unlike conventional heartworm preventive drugs that have a short half-life and must be administered daily or monthly, when microparticles containing moxidectin are administered, moxidectin is continuously released for more than three months, thereby maintaining the preventive effect against heartworms. In addition, by producing microparticles with a constant average particle diameter and a narrow diameter distribution, it is possible to prevent initial excessive release of moxidectin even when the microparticles are administered, and to control the release of the drug to maintain a constant concentration of effective moxidectin for more than three months, thereby reducing foreign body sensation and pain when the injection is administered.

The present invention provides compositions and methods for the multiplex detection of biomarkers in an environmental, non-biological or biological sample. Compositions and methods are provided for simultaneously detecting and identifying multiple pathogens, including viruses, bacteria, fungi, protozoa and helminths, present in a sample.

The invention discloses an application of kochia saponin in preparation of a medicine for treating helminthosis, an in-vitro effectiveness experiment result of the kochia saponin on an echinococcosis multilocularis protoscolex shows that the killing effect of the kochia saponin on the protoscolex has time and concentration dependence, the death rates of 10 [mu] M, 20 [mu] M and 50 [mu] M of kochia saponin treated for 6 h are 8.05% + / -0.39%, 89.23% + / -1.48% and 100% respectively, and the death rates of 10 [mu] M, 20 [mu] M and 50 [mu] M of kochia saponin treated for 24 h are all 100%; meanwhile, results of in-vitro effectiveness experiments of kochia saponin on trichina at different development stages show that after the trichina is treated for 72 hours under the concentration of 50 mu M, 80 mu M and 100 mu M, the death rates of muscular larvae are 86.24% + / -1.15%, 90.17% + / -1.24% and 90.86% + / -2.10% respectively; after treatment for 24 hours, the death rates of the newborn larvae are respectively 12.71% + / -2.36%, 57.80% + / -2.23% and 79.60% + / -1.52%, all the newborn larvae die after 48 hours, and the killing effect is obvious. Besides, the applicant confirms that the mogroside can directly destroy the epidermis structure and cell integrity of the insect body for the first time through microscope observation, and the discovery provides visual morphological evidence for the anti-parasitic effect of the mogroside.

A compound of formula (I), (IA) or formula (II) or a composition comprising the compound of formula (I), (IA) or formula (II) in association with a veterinarily acceptable carrier are described. A method of controlling helminths using same is described.

The present invention relates to a vaccine comprising a recombinant antigen derived from a parasitic nematode, Stronchus annulata, which will produce an immune response in cultured and wild ruminants susceptible to or prone to being infected with one or more nematode helminth species.

A vibrational system for attracting worms comprising having a ground insertion end at a distal portion, a grasping end at a proximal portion, and a plurality of coils at an intermediate portion between the distal portion and the proximal portion spaced apart to provide axially spaced apart gaps between the plurality of coils. The plurality of coils are configured to emit a vibration that attracts worms upon strumming of the coils. A strummer can be provided as a separate component unattached to the vibrational device to engage the coils.

Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli, the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium bovis, or Enterobacter cloacae. The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. Further embodiments provide compositions comprising arsinothricin or a salt thereof and an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.